News
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback